9704 MEDICAL CENTER DRIVE, Rockville, MD
Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position
Provides Clinical Update on Ongoing Phase 1 Study for MGC026
Director Resignation - Karen Ferrante Steps Down from Board
Completes Sale of GMP Manufacturing Operations to Bora Pharmaceuticals
MacroGenics, Inc. Annual Meeting - Stockholder Votes on Director Elections
Reports First Quarter 2026 Financial Results and Highlights Business Transformation
To Sell GMP Manufacturing Operations to Pharmaceuticals
And Sagard Healthcare Partners Enter into Expanded ZYNYZ® Royalty Purchase Agreement
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report